Browse Category:


[Search within category]

Small Molecule Generation of Multinucleated and Striated Myofibers from Human Pluripotent Stem Cells Equivalent to Adult Skeletal Muscle

Researchers in the UCLA Department of Microbiology, Immunology and Molecular Genetics have developed a novel means of generating adult skeletal muscle-equivalent myofibers from human pluripotent stem cells.

CRISPR/Cas9 Mediated Genome Editing For Duchenne Muscular Dystrophy

UCLA researchers in the Department of Microbiology, Immunology & Molecular Genetics have developed a method to permanently correct the out-of-frame dystrophin gene in patient cell models of Duchenne Muscular Dystrophy (DMD)

Stem Cell Therapy For Dysphagia Due To Tongue Atrophy

UCLA researchers have developed a novel method to treat dysphagia due to tongue atrophy via the transplantation of multipotent or differentiated stem cells.

Biomarkers Of Response And Synergistic Combinations With ERK Targeted Therapies In Human Cancers

UCLA researchers have identified a set of genomic markets that identify a group of human cancer cell lines more likely to respond to ERK1/2 inhibitors. These markers are believed to be critical in identifying those patients that will most likely respond to ERK1/2 inhibition used in cancer therapy.

Biomarkers Of Response To Cyclin D - CDK4/6 Targeted Therapies In Human Cancers

UCLA researchers have identified 9 genetic response markers that may play a mechanistic role in determining sensitivity or resistance to treatment with the CDK-4/6 and cyclin D inhibitors.

Biomarkers Of Response To Inhibition Of Poly-Adp Ribose Polymerase (PARP) In Human Cancers

The Slamon and Finn groups at UCLA have discovered that specific chromosomal gains can serve as biomarkers that predict a cancer patient response to treatments that use poly-ADP ribose polymerase (PARP) inhibitors.

Methods And Device For Use Of Phase Locked High Frequency Oscillations To Distinguish The Epileptogenic Ictal Core

UCLA researchers have developed a method and device for the automatic identification of phase-locked high-frequency oscillations to localize epileptogenic brain for neurological intervention.

Novel therapeutic approach for obesity: Pharmacological targeting of Kv1 potassium channels

Obesity is a global epidemic that is in need of novel and safe therapeutics. Despite the enormous efforts by pharmaceutical companies, there is a shortage for safe therapeutics for obesity. Researchers at UCI have developed a selective inhibitor of Kv1.3 potassium channel, ShK-186, which displays powerful anti-obesity effects in a mouse model of diet-induced obesity. Using critical experimental measures, researchers highlight the potential use of Kv1.3 blockers in the treatment of obesity and insulin resistance.

New Compounds For The Treatment Of Diseases Related To Protein Misfolding

UCLA researchers in the Department of Neurology with an international team of scientists have developed compounds for therapeutic use in protein misfolding diseases.

Thrombospondins as a target to treat neuropathic pain

Neuropathic pain is a common problem, though, there are few existing pain medications have specific targets to treat this type of pain, and often lack efficacy and tolerance. The invention identifies specific proteins and related genes as targets for treating neuropathic pain in an animal model.

ShK-K22DAP, an immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of T-cells

Blocking of potassium channels in T cells is a promising therapeutic approach for treatment of chronic autoimmune diseases. Researchers at UCI have developed a potent peptide inhibitor of potassium channels that has high affinity and is >100 fold selective to a specific potassium channel, Kvl.3, over others.

Stimuli Responsive Immunostimulants

An immune response typically occurs during inflammation, auto-immune diseases, or cancers. In such cases, chemical triggers, or immunostimulants, recognized by receptor proteins at cell membranes activate the immune cells. Researchers can use these immunostimulants to test how different cell subsets contribute to immune response mechanisms. This invention describes a novel type of immunostimulant that can be toggled on and off, both inside the body and in vitro.

Ligands for Improved Angiogenesis and Endothelialization of Blood Contacting Devices

Researchers at the University of California, Davis have discovered novel targeting ligands that can specifically bind and capture endothelial cells and endothelial progenitors for improved endothelialization and angiogenesis of medical devices and scaffolds.

Re-Sensitizing Cancer Cells to Anticancer Drugs

Researchers at the University of California, Davis have discovered a new class of ROR-γ inhibitors which can reduce and reverse cancer cell resistance to anticancer drugs.

Novel Solid Tumor Chemodrug LLS2

Researchers at the University of California, Davis have developed a new library of small molecule LLS2 that can kill a variety of cancer cells

Mi-181: A Potent Small Synthetic Microtubule-Targeting Anticancer Agent

UCLA researchers in the Department of Chemistry & Biochemistry and Department of Molecular & Medical Pharmacology have discovered compound MI-181 and successfully synthesized its derivatives and analogs, which have the potential for use in cancer therapy by arresting cells during the process of cell division and promoting apoptosis.

Therapeutic strategies for Huntington’s Disease using stop codon suppression

In Huntington’s Disease (HD), aberrant splicing of the huntingtin protein can produce a highly toxic peptide that accumulates in the brain. The invention describes methods to minimize the toxicity of spliced proteins.

Antibodies targeting mammalian Sterol Regulatory Element Binding Proteins (SREBP) 1 and 2

Sterol Regulatory Element Binding Proteins (SREBP) are important factors that control lipid homeostasis in mammals. Researchers at UCI have prepared antibodies that have good affinity and specificity for human SREBP1/2 for use as research tools. These antibodies have application in genetic and immunotherapeutic research areas.

Induced Pluripotent Stem Cell-Derived Glial Enriched Progenitor Cells For The Treatment Of White Matter Stroke

UCLA researchers in the Department of Neurology and the Department of Molecular, Cell & Developmental Biology have developed novel therapies for cerebral ischemic injuries, including white matter stroke, using glial-enriched progenitor cells.

Accessing Spinal Networks To Enable Autonomic Function

UCLA researchers have developed a strategy to rehabilitate and train the spinal cord so that normal bladder/bowel function can be restored. Once trained, voluntary control of bladder/bowel function is present even without stimulation.

Wireless Wearable Big Data Brain Machine Interface (W2b2/Wwbb)

UCLA researchers have developed a wireless wearable big data brain machine interface. This technology provides a user-friendly brain machine interface system that can monitor/record a large amount of brain activities and transfer, wirelessly, the processed/raw data to a remote mobile unit.

Electronically controllable laser and point location system for body worn laser therapeutic systems

Photonic physiological and neurological stimulation is the application of therapeutic lasers to classical acupuncture points on the body for therapeutic purposes. The therapy is typically delivered with a manually held and adjusted laser, which can be inexact and unsteady. Working together, inventors at UCI and Samueli Institute have developed a computer-controlled photonic stimulation system that is capable of using complex therapy protocols to provide more effective treatment using multiple laser sources.

PVA nanocarrier system for controlled drug delivery

Researchers at the University of California, Davis have designed and synthesized a unique type of water-soluble, biodegradable targeting poly(vinyl alcohol) (PVA) nanocarrier system for controlled delivery of boronic acid containing drugs, chemotherapy agents, proteins, photodynamic therapy agents and imaging agents.

Enhanced Cell/Bead Encapsulation Via Acoustic Focusing

The invention consists of a multi-channel, droplet-generating microfluidic device with a strategically placed feature. The feature vibrates in order to counteract particle-trapping micro-vortices formed in the device. Counteracting these vortices allows for single particle encapsulation in the droplets formed by the device and makes this technology a good candidate for use in single cell diagnostics and drug delivery systems.

Aptamers that promote neuronal growth by binding to and blocking the protein Nogo

Neuronal growth inhibiting protein (Nogo), blocks regrowth of damaged neuronal projections (axons) in neurodegenerative disorders. Currently, researchers are developing antibody proteins to inhibit Nogo and produce axon regrowth in a variety of disorders. However, such antibodies are unstable and costly to synthesize. At UCI, the synthesis of nucleic acid molecules called aptamers that selectively bind and block Nogo to promote axonal growth presents a promising alternative pharmaceutical target for treating a range of disorders including spinal cord injury, stroke, Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS).

  • Go to Page: